Differentially expressed genes in HIV-1-infected macrophages following treatment with the virus-suppressive immunomodulator murabutide

Virus Research

Volumn 99, Issue 1, 2004, Pages 25-33

  Truong, Marie José ^a   Delsart, Véronique ^a   Bahr, George M ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Differential display; HIV 1; Monocyte derived macrophages; Murabutide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BINDING PROTEIN; COMPLEMENTARY DNA; DNA BINDING PROTEIN; DRUG DERIVATIVE; IMMUNOMODULATING AGENT; MURABUTIDE; N ACETYLMURAMYL ALANYLGLUTAMINE N BUTYL ESTER; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; N-ACETYLMURAMYL-ALANYLGLUTAMINE-N-BUTYL ESTER; OCTAMER BINDING FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR OTF-1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DIFFERENTIAL DISPLAY; DNA BINDING; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL INFECTION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC CODE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; MACROPHAGE; METABOLISM; METAL BINDING; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; UPREGULATION; VIROLOGY; VIRUS INFECTION; VIRUS INHIBITION; VIRUS TRANSCRIPTION; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0347480212     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2003.09.011     Document Type: Article

References (50)

1. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 215:1990;403-410.
2. Amiel C., De La Tribonniere X., Vidal V., Darcissac E., Mouton Y., Bahr G.M. Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1- infected patients. J. AIDS. 30:2002;294-305.
3. Aquaro S., Calio R., Balzarini J., Bellocchi M.C., Garaci E., Perno C.F. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 55:2002;209-225.
4. Atar D., Backx P.H., Appel M.M., Gao W.D., Marban E. Excitation- transcription coupling mediated by zinc influx through voltage-dependent calcium channels. J. Biol. Chem. 270:1995;2473-2477.
5. Baeuerle P.A. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim. Biophys. Acta. 1072:1991;63-80.
6. Bahr G.M. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J. Antimicrob. Chemother. 51:2003;5-8.
7. Bahr G.M., Darcissac E., Bevec D., Dukor P., Chedid L. Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacol. 17:1995;117-131.
8. Bahr G.M., Darcissac E.C., Casteran N., Amiel C., Cocude C., Truong M.J., Dewulf J., Capron A., Mouton Y. Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J. Virol. 75:2001;6941-6952.
9. Bahr G.M., De La Tribonniere X., Darcissac E., Ajana F., Bocket L., Sissoko D., Yazdanpanah Y., Dewulf J., Amiel C., Mouton Y. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term anti-retroviral treatment. J. Antimicrob. Chemother. 51:2003;1377-1388.
10. Cano-Gauci D.F., Sarkar B. Reversible zinc exchange between metallothionin and the estrogen receptor zinc finger. FEBS Lett. 386:1996;1-4.
11. Chougnet C., Shearer G.M., Landay A.L. The role of antigen-presenting cells in HIV pathogenesis. Curr. Infect. Dis. Rep. 4:2002;266-271.
12. Chun T.W., Fauci A.S. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10958-10961.
13. Cocude, C., Truong, M.J., Billaut-Mulot, O., Delsart, V., Darcissac, E., Capron, A., Mouton, Y., Bahr, G.M., A novel cellular helicase, RH 116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication, J. Gen. Virol. 84, in press.
14. Darcissac E.C., Truong M.J., Dewulf J., Mouton Y., Capron A., Bahr G.M. The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J. Virol. 74:2000;7794-7802.
15. Durnam D.M., Palmiter R.D. Transcriptional regulation of the mouse metallothionin-I gene by heavy metals. J. Biol. Chem. 256:1981;5712-5716.
16. Dvir A., Tan S., Conaway J.W., Conaway R.C. Promoter escape by RNA polymerase. II. Formation of an escape-competent transcriptional intermediate is a prerequisite for exit of polymerase from the promoter. J. Biol. Chem. 272:1997;28175-28178.
17. Goasduff T., Darcissac E.C., Vidal V., Capron A., Bahr G.M. The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator. Clin. Exp. Immunol. 128:2002;474-482.
18. Goodrich J.A., Tjian R. Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell. 77:1994;145-156.
19. Grenfell S.J., Latchman D.S., Thomas N.S.B. Oct-1 and Oct-2 DNA-binding site specificity is regulated in vitro by different kinases. Biochem. J. 315:1996;889-893.
20. Guo J., Wu T., Anderson J., Kane B.F., Johnson D.G., Gorelick R.J., Henderson L.E., Levin J.G. Zinc finger structures in the human immunodeficiency virus type 1 nucleocapsid protein facilitate efficient minus- and plus-strand transfer. J. Virol. 74:2000;8980-8988.
21. Holstege F.C., Tantin D., Carey M., van der Vliet P.C., Timmers H.T. The requirement for the basal transcription factor IIE is determined by the helical stability of promoter DNA. EMBO J. 14:1995;810-819.
22. Honda Y., Rogers L., Nakata K., Zhao B.Y., Pine R., Nakai Y., Kurosu K., Rom W.N., Weiden M. Type 1 interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)β, repressing the HIV-1 long-terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J. Exp. Med. 188:1998;1255-1265.
23. Kang S.W., Kuzuhara T., Horikoshi M. Functional interaction of general transcription initiation factor TFIIE with general chromatin factor SPT16/CDC68. Genes Cells. 5:2000;251-263.
24. Kashanchi F., Piras G., Radonovich M.F., Duvall J.F., Fattaey A., Chiang C.M., Roeder R.G., Brady J.N. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature. 367:1994;295-299.
25. Kugel J.F., Goodrich J.A. A kinetic model for the early steps of RNA synthesis by human RNA polymerase II. J. Biol. Chem. 275:2000;40483-40491.
26. Levy J.A. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 22:2001;312-316.
27. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
28. Liu Y.Z., Latchman D.S. The octamer-binding proteins Oct-1 and Oct-2 repress the HIV long terminal repeat promoter and its transactivation by Tat. Biochem. J. 322:1997;155-158.
29. Mahlknecht U., Herbein G. Macrophages and T-cell apoptosis in HIV infection: a leading role for accessory cells? Trends Immunol. 22:2001;256-260.
30. Mely Y., De Rocquigny H., Morellet N., Roques B.P., Gerad D. Zinc binding to the HIV-1 nucleocapsid protein: a thermodynamic investigation by fluorescence spectroscopy. Biochemistry. 35:1996;5175-5182.
31. Orenstein J.M., Fox C., Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science. 276:1997;1857-1861.
32. Pouillart P.R., Audibert F.M., Chedid L.A., Lefrancier P.L., Bahr G.M. Enhancement by muramyl peptides of the protective response of interferon-α/β against encephalomyocarditis virus infection. Int. J. Immunopharmacol. 18:1996;183-192.
33. Reid G. Specific toxins destabilize virus inhibitors (e.g. AIDS viruses). Med. Hypotheses. 54:2000;917-918.
34. Riss J., Laskov R. Expression of novel alternatively spliced isoforms of the oct-1 transcription factor. Biochim. Biophys. Acta. 1444:1999;295-298.
35. Sato M., Bremner I. Oxygen free radicals and metallothionin. Free Radic. Biol. Med. 14:1993;325-337.
36. Schreiber E., Matthias P., Muller M.M., Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucl. Acids Res. 17:1989;6419.
37. Scott M.P., Tamkun J.W., Hartzell G.W. III The structure and function of the homeodomain. Biochim. Biophys. Acta. 989:1989;25-48.
38. Summers M.F., South T.L., Kim B., Hare D.R. High-resolution structure of an HIV zinc fingerlike domain via a new NMR-based distance geometry approach. Biochemistry. 29:1990;329-340.
39. Thornalley P.J., Vasak M. Possible role for metallothionin in protection against radiation-induced oxidative stress: kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim. Biophys. Acta. 827:1985;36-44.
40. Timmers H.T. Transcription initiation by RNA polymerase II does not require hydrolysis of the β-γ phosphoanhydride bond of ATP. EMBO J. 13:1994;391-399.
41. Truong M.J., Darcissac E.C., Hermann E., Dewulf J., Capron A., Bahr G.M. Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. J. Virol. 73:1999;7008-7013.
42. Vidal V., Dewulf J., Bahr G.M. Enhanced maturation and functional capacity of monocyte-derived immature dendritic cells by the synthetic immunomodulator murabutide. Immunology. 103:2001a;479-487.
43. Vidal V.F., Casteran N., Riendeau C.J., Kornfeld H., Darcissac E.C., Capron A., Bahr G.M. Macrophage stimulation with murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPβ and STAT1: role of CD14 and Toll- like receptors 2 and 4. Eur. J. Immunol. 31:2001b;1962-1971.
44. Yokomori K., Verrijzer C.P., Tjian R. An interplay between TATA box-binding protein and transcription factors IIE and IIA modulates DNA binding and transcription. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6722-6727.
45. Zaitseva M., Lee S., Lapham C., Taffs R., King L., Romantseva T., Manischewitz J., Golding H. Interferon γ and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection. Blood. 96:2000;3109-3117.
46. Zeng J., Heuchel R., Schaffner W., Kagi J.H. Thionein (apometallothionin) can modulate DNA binding and transcription activation by zinc finger containing factor Sp1. FEBS Lett. 279:1991a;310-312.
47. Zeng J., Vallee B.L., Kagi J.H. Zinc transfer from transcription factor IIIA fingers to thionein clusters. Proc. Natl. Acad. Sci. U.S.A. 88:1991b;9984-9988.
48. Zhou M., Kashanchi F., Jiang H., Ge H., Brady J.N. Phosphorylation of the RAP74 subunit of TFIIF correlates with Tat-activated transcription of the HIV-1 long terminal repeat. Virology. 268:2000;452-460.
49. Zhu T., Muthui D., Holte S., Nickle D., Feng F., Brodie S., Hwangbo Y., Mullins J.I., Corey L. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active anti-retroviral therapy. J. Virol. 76:2002;707-716.
50. Zybarth G., Reiling N., Schmidtmayerova H., Sherry B., Bukrinsky M. Activation-induced resistance of human macrophages to HIV-1 infection in vitro. J. Immunol. 162:1999;400-406.